BioNTech grabs PD-L1/VEGF bispecific with $55M upfront, expanding pipeline while lowering Covid guidance
As BioNTech continues to beef up its oncology pipeline, it’s once again turning to a Chinese partner.
The German biotech is putting down $55 million upfront for a collaboration deal with Biotheus, which is based out of Zhuhai, China. In return, BioNTech will get a global ex-China license of PM8002, a bispecific simultaneously targeting PD-L1 and VEGF now being tested in Phase II studies in China, the companies said Monday morning. BioNTech returned to the region after striking two antibody-drug conjugate pacts earlier this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.